Stubbs R S, Alwan M H, Booth M W
Wakefield Clinic for Gastrointestinal Diseases, Wakefield Hospital, Wellington, New Zealand.
HPB Surg. 1998;11(2):97-104. doi: 10.1155/1998/49496.
This paper presents an experience of thirty consecutive patients with hepatic colorectal metastases who were treated with hepatic cryotherapy and subsequent hepatic arterial infusion (HAI) chemotherapy using 5 FU. Patients with colorectal metastases confined to the liver but not suitable for resection, and with liver involvement of less than 50% were offered the treatment. Prospective documentation of all patients was undertaken with data being recorded on a computerised database. Patients had a median of 6 (2-15) lesions with sizes ranging from 1-12 cm. There was no 30 day mortality. Postoperative complications developed in 8 patients but were followed by full recovery in all instances. Side effects from chemotherapy occurred in 23% of cycles. Twenty seven patients have died. Median survival from the time of cryotherapy was 18.2 months (7-34), or 23 months (9-44) from diagnosis of liver lesions. Hepatic cryotherapy with subsequent arterial chemotherapy is safe and well tolerated. The results suggest survival of patients with colorectal hepatic metastases can be improved by the use of this modality of treatment.
本文介绍了连续30例肝结直肠癌转移患者接受肝脏冷冻治疗及随后使用5-氟尿嘧啶进行肝动脉灌注(HAI)化疗的经验。将局限于肝脏但不适合切除且肝脏受累小于50%的结直肠癌转移患者纳入该治疗。对所有患者进行前瞻性记录,数据记录在计算机数据库中。患者的病灶中位数为6个(2 - 15个),大小范围为1 - 12厘米。无30天死亡率。8例患者出现术后并发症,但均完全康复。化疗副作用发生在23%的疗程中。27例患者死亡。从冷冻治疗时起的中位生存期为18.2个月(7 - 34个月),从肝脏病灶诊断时起为23个月(9 - 44个月)。肝脏冷冻治疗及随后的动脉化疗安全且耐受性良好。结果表明,使用这种治疗方式可提高结直肠癌肝转移患者的生存率。